Background:
INTRODUCTION
The heart contains high levels of all PPARs, little is known about how PPARs ligands affect cardiac functions (Brandt et al., 1998). Nothing is known about the role of PPARs in cardiac diseases (Bailey, 2000). It is still unclear whether PPARs agonists are beneficial or harmful for heart failure cases (Chen et al., 2008) . In addition to that Robins et al. (2001) reported that fibrates (PPARs agonists) produce a significant reduction in coronary heart disease in patients with low HDL cholesterol levels.
The cardiovascular effect of fibrates was studied by many authors who mentioned that fibrates exert beneficial effects in prevention of cardiovascular diseases through activation of PPAR-α which seems to protect the heart from ischemia/reperfusion myocardial injury (Yue et al., 2003) . PPAR-α ligands not only reduce the incidence of cardiovascular diseases but also their cardioprotective efficacy is higher in dyslipidemic patient with diabetes or hyperinsulinemia, in which the cardiovascular diseases are the major cause of mortality ( From another point of view, the effect of PPARs activation on diseased heart was mentioned by Schiffrin (2005) who reported that, PPAR-α is expressed in cardiomyocytes and regulates gene expression of key proteins involved in myocardial lipid and energy metabolism. PPAR-α activity may significantly contribute to cardiac hypertrophy and overall cardiovascular remodeling. In addition, Goikoetxea et al. (2004) reported that, under conditions of pressure overload, there is suggestion of a potential role of PPAR-α in the transition from compensated heart hypertrophy to heart failure in hypertensive heart disease.
Moreover It was concluded that, PPAR-α agonists have demonstrated significant anti-inflammatory activity that seem to play not only a role in their protective actions within the cardiovascular system So this work was performed to study the pharmacological effect on some cardiovascular preparation including experiments on isolated cardiac muscle, coronary flow, spiral aortic strips & arterial blood pressure . Its possible mechanism of action was also done .
MATERIALS AND METHODS
Gemfibrozil was supplied in the form of tablets which were film coated Each tablet contained 600mg gemfibrozil which was dissolved in distilled water . It was tested on the following strips:
I-In-vitro study  Experiments on isolated perfused rabbit heart and coronary flow: (The staff of the department of pharmacology, Edinburgh, 1970).
The effect of test drug on cardiac contractions was obtained using gradually increasing doses of gemfibrozil (25-800μg/ml) and coronary flow. For site of action of gemfibrozil (100μg/ml), the effect of test drug (100μg/ml) on the amplitude of myocardial contractions was recorded before and after complete blockade of nicotinic and muscrinic cholinergic receptors by appropriated doses of nicotinic (10µg/ml) and atropine (10µg/ml). Also the effect of gemfibrozil was tested on calcium channels using calcium glucoicate (300 µg/ml) ; in addition its effect on isoprenaline (0.3µg/ml), histamine (0.05µg/ml), serotanine (0.1µg/ml) induced myocardial contractions and after Larginine (inhibitor of nitric oxide synthase , NOS)  Experiments on isolated aortic spiral strips of rabbit (Furchgott and Bhadrakom, 1984):
The effect of gemfibrozil (25-800ug/ml) on the NE-induced contractions was tested after incubation 35 minutes. The experiment was done on six prepartions .
II-In-vivo study
 Experiments on arterial blood pressure of anaesthetized cats (The staff of the department of pharmacology, Edinburgh, 1970).
The effect of gemfibrozil (1-8 mg/kg-iv ) on mean arterial blood pressure of anaesthetized cats was recorded.
Statistical analysis: Statistical analysis was done using SPSS 14.0 for windows. Significant value was considered when p value <0.05. Student t-test of significant was used (Steel and Torrie, 1964).
RESULTS

I-In-vitro study:
 Experiments on isolated perfused rabbit heart and coronary flow:
Gemfibrozil (25-800μg/ml) produced a dose-dependent reduction on the amplitude of myocardial contractions (Fig.1) . The mean percent reduction ± SEM ranged from 22.97 ± 1.87 to 85.65 ± 3.81 and was found to be statistically significant Table (1), (Fig.2) . On coronary flow (ml/min) Gemfibrozil (25-800μg/ml): Gemfibrozil (25-800μg/ml) produced a dose-dependent reduction of coronary flow. The mean percent reduction ± SEM ranged from 20.92 ± 2.83 to 87.48 ± 2.94 and was found to be statistically significant (Table 2) . { Gemfibrozil (100μg/m)} produced reduction of the amplitude of myocardial contractions after complete blockade of nicotinic and muscarinic receptors. The stimulant effect of either calcium gluconate (300μg/ml), Isoprenaline (0.3μg/ml), histamine (0.05μg/ml), or serotonin (0.1μg/ml), on the amplitude of myocardial contractions was not abolished after administration of gemfibrozil (100μg/ml). On the other hand , the inhibitory effect of gemfibrozil (100μg/ml) on the amplitude of myocardial contractions was completely abolished after inhibition of nitric oxide synthase by N-methyl L-arginine (100μg/ml) ( Fig.2-8 ).
 Experiments on isolated rabbit aortic spiral strips:
Gemfibrozil (25-800μg/ml) produced a dose-dependent significant reduction on the NE-induced contractions. The mean percent reduction ± SEM ranged from 5.31 ± 1.42 to 65.14 ± 5.32 and was found to be statistically significant while the first dose (25ug/ml) has no effect Table ( 3), (Fig.9 ).
II-In-vivo study:
 Experiments on mean arterial blood pressure of anaesthetized cats:
Gemfibrozil (5-160mg/kg-iv) produced a dose-depended reduction on the mean arterial blood pressure of anaesthetized cats. The mean percent reduction ± SEM ranged from 8.17 ± 1.40 to 58.2 ± 3.1 and was found to be statistically significant Table (4), (Fig. 10) .
Table (1):
Mean % reduction caused by gemfibrozil (25-800 μg/ml) on the amplitude of myocardial contractions (cm) of isolated perfused rabbit heart (Mean % ± SEM). 
Doses
Figure (2):
Effect of gemfibrozil (100μg/ml) on the amplitude of myocardial contractions of isolated perfused rabbit heart after complete blockade of nicotinic receptors.
Figure (3):
Effect of gemfibrozil (100μg/ml) on the amplitude of myocardial contractions of isolated perfused rabbit heart after complete blockade of muscarinic receptors.
Figure (4):
Effect of gemfibrozil (100μg/ml) on calcium gluconate-induced contraction of isolated perfused rabbit heart. 
DISCUSSION
In the present work, the experiments on isolated perfused rabbit heart showed that, gemfibrozil (fibrate, PPAR-α agonist) (25-800μg/ml) produced a significant reduction on the amplitude of myocardial contractions in a dose dependant manner. This negative inotropic effect is in agreement with In the present study, the mechanism of the negative inotropic effect of gemfibrozil showed that the effect was completely abolished after inhibition of nitric oxide synthase (NOS) suggesting that it may be mediated through stimulation of NOS. The depressant effect of rosiglitazone; (another PPAR agonist which stimulate γ type) was attributed also to increasing NO production The role of NO on heart function was discussed by many authors. A study by Massion et al. (2003) had reported that all three isoforms of NOS (endothelial, neural and inducible) are expressed in cardiomyocytes themselves and NO regulates cardiac function through direct effect on several aspects of cardiomyocytes contractility, starting from the fine regulation of excitation-contraction coupling to modulation of (presynaptic and postsynaptic) autonomic signaling and mitochondrial respiration. The same authors added also that, excessive NO delivery may result in profound cellular disturbances leading to heart failure. Concerning the effect of gemfibrozil on coronary flow of isolated perfused rabbit heart, the present study revealed that gemfibrozil (25-800μg/ml) reduced the coronary flow significantly in a dose dependant manner. This result seems to disagree with other studies which support the beneficial effect of gemfibrozil in coronary heart disease and the reduction in coronary flow may be attributed to the significant reduction in myocardial contractility as illustrated by Ramanathan and Skinner (2005) who reported that in case of heart failure there is impaired ejection that results in large diastolic volume which cause elevation in the left ventricular end diastolic pressure (LVEDP) so the coronary perfusion pressure is reduced. The relation between LVEDP and coronary perfusion pressure is mentioned also by Kaplan et al. (1999) who mentioned that the coronary perfusion pressure is the difference between the aortic diastolic pressure and LVEDP. So when LVEDP is elevated due to reduction in myocardial contractility caused by gemfibrozil, the coronary blood flow is reduced. So our results concluded that gemfibrozil which is a member of fibrate and one of the most drugs in hypertiglyceridemias can be effective in hypertensive atherosclerotic patient . However it must be used cautiously in patients with impaired myocardiam . 
